{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T08:13:29Z","timestamp":1771661609329,"version":"3.50.1"},"reference-count":0,"publisher":"Elsevier BV","issue":"4","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMP"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>A chronic metabolic disease, diabetes mellitus (DM), is associated with various comorbidities\nthat considerably decrease the quality of life. Sodium glucose linked transporter 2 (SGLT2)\nreceptors are mainly situated in the proximal tubule of nephron. About 90% of glucose concentration\nis reabsorbed by these receptors in the nephron. The advanced remedy for the management of\nDM is sodium glucose co-transporter 2 inhibitors (SGLT2-Is), which inhibits or lowers the reabsorption\nof glucose. Furthermore, SGLT2-Is enhance the elimination of glucose level in urine (glycosuria).\nEmpagliglozin, canagliflozin, ertugliflozin and dapagliflozin are the standard medications\nwhich have been authorized recently, for the management of DM by The Food and Drug Administration\n(FDA). Besides, having optimistic efficacy to attenuate blood glucose level, these medications\nhave exhibited impressive cardioprotective and renoprotective effects in major clinical trials.\nUnlike other hypoglycaemic medications, it is found that these agents help in a consistent reduction\nin hospitalization, due to heart failure with probably multifactorial mechanisms. The cardioprotective\nefficacy of SGLT2-Is is characterized by enhancement in ventricular loading condition, in\nmetabolism of cardiac cell, adipokines alteration, cardiac fibrosis, and reduction in the necrosis of\ncardiac cell. Recently confirmed results depict that dapagliflozin gradually decreases the frequency\nof co-morbidity and mortality in heart failure patients. The present review explores the mechanistic\nprinciple and the clinical trial data of SGLT2-Is, which further support cardioprotective effects associated\nwith these medications.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1874467213666201012161439","type":"journal-article","created":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T07:17:07Z","timestamp":1602573427000},"page":"487-497","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["SGLT-2 Inhibitors: Ideal Remedy for Cardioprotection in Diabetes Mellitus"],"prefix":"10.1016","volume":"14","author":[{"given":"Keshav","family":"Kumar","sequence":"first","affiliation":[{"name":"Chitkara College of Pharmacy, Chitkara University, Punjab,India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0993-7708","authenticated-orcid":true,"given":"Tapan","family":"Behl","sequence":"additional","affiliation":[{"name":"Chitkara College of Pharmacy, Chitkara University, Punjab,India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arun","family":"Kumar","sequence":"additional","affiliation":[{"name":"Chitkara College of Pharmacy, Chitkara University, Punjab,India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandeep","family":"Arora","sequence":"additional","affiliation":[{"name":"Chitkara College of Pharmacy, Chitkara University, Punjab,India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","container-title":["Current Molecular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download\/186794","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/186794\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download\/186794","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T22:57:09Z","timestamp":1746572229000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/186794\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":0,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1874467213666201012161439","relation":{},"ISSN":["1874-4672"],"issn-type":[{"value":"1874-4672","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-04-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-18","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}